

FORM PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket  
P29491Application No.  
10/517,324INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(Use several sheets if necessary) NOV 27 2006

Applicant  
Susumo MUTO et al.Filing Date  
I.A. Filed September 3, 2004Group  
Not Yet Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	8 - 0 9 5 2 0 8	04/12/96	JAPAN			
	60 - 1 5 6 3 8 7	08/16/85	JAPAN			
	0 0 / 3 2 5 9 8	06/08/06	W.I.P.O.			
	0 1 / 5 7 0 0 6	08/09/01	W.I.P.O.			
	1 1 1 9 4 3 6	12/14/61	GERMANY			
	2004 / 0 2 4 0 6 1	03/25/04	W.I.P.O.			
	9 5 / 3 2 1 9 0	11/30/95	W.I.P.O.			
	9 5 / 2 1 8 3 2	08/17/95	W.I.P.O.			
	2 3 7 2 7 4 0	09/04/02	UNITED KINGDOM			
	03 / 0 0 0 2 5 3	01/03/03	W.I.P.O.			
	03 / 0 0 0 2 5 8	01/03/03	W.I.P.O.			
	03 / 0 0 0 6 4 9	01/03/03	W.I.P.O.			
	03 / 0 0 0 6 7 1	01/03/03	W.I.P.O.			
	03 / 0 0 0 6 8 4	01/03/03	W.I.P.O.			
	02 / 0 6 4 0 6 8	08/22/02	W.I.P.O.			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1	English Language Abstract of JP 8-095208.
2	English Language Abstract of JP 60-156387.
3	English Language Chemical Abstract of DE 11 19 436.
4	SCHNEIDERMAN et al. "Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries", Proceedings in the National Academy of Science U.S.A., vol. 89 (1992), pp. 6998-7002.
5	ERICKSON et al. "Development of Venous Occlusions in Mice Transgenic for the Plasminogen Activator Inhibitor-1 gene", Nature, vol. 346 (1990), pp. 74-76.
6	SAMAD et al. "Tissue Distribution and Regulation of the Plasminogen Activator Inhibitor-1 in Obese Mice", Molecular Medicine, vol. 2, No. 5 (1996), pp. 568-582.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application No.  
10/517,324

(Use several sheets if necessary)

PATENT OFFICE  
 NOV 27 2006  
 PATENT OFFICE

Group  
Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- |    |  |
|----|--|
| 7  | SCHÄFER et al. "Disruption of the Plasminogen Activator Inhibitor 1 Gene reduces the Adiposity and improves the Metabolic Profile of Genetically Obese and Diabetic ob/ob Mice", <i>FASEB Journal</i> , vol. 15, No. 10 (2001), pp. 1840-1842. |
| 8  | TSUCHIYA et al. "The Antibody to Plasminogen Activator Inhibitor-1 suppresses Pulmonary Metastases of Human Fibrosarcoma in Athymic Mice", <i>General and Diagnostic Pathology</i> , vol. 141 (1995), pp. 41-48.                               |
| 9  | BAJOU et al. "Absence of Host Plasminogen and Activator Inhibitor-1 prevents Cancer Invasion and Vascularization", <i>Nature Medicine</i> , vol. 4, no. 6 (1998), pp.923-928.  |
| 10 | CHO et al. "Production of Plasminogen Activator Inhibitor-1 by Human Mast Cells and Its Possible Role in Asthma", <i>The Journal of Immunology</i> , vol.165, no. 6 (2000), pp. 3154-3161.   |
| 11 | OH et al. "PAI-1 promotes Extracellular Matrix Deposition in the Airways of a Murine Asthma Model", <i>Biochemical and Biophysical Research Communications</i> , vol. 294 (2002), pp. 1155-1160.   |
| 12 | BJÖRQUIST et al. "Identification of the Binding Site for a Low-Molecular-Weight Inhibitor of Plasminogen Activator Inhibitor Type 1 by Site-Directed Mutagenesis", <i>Biochemistry</i> , vol. 37 (1998), 1227-1234.                            |
| 13 | MITSUMOBU "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products", <i>Synthesis</i> (1981), pp. 1-28.   |
| 14 | DÜRÜST "A New and Convenient Synthesis of some Substituted Thiohyndantoins", <i>Synthetic Communications</i> , vol. 29, no. 11 (1999), pp. 1997-2005.  |
| 15 | KOZUMA "Drug Eluting Stent", <i>Coronary Intervention</i> , vol. 1, no. 1 (2002), pp. 58-62, accompanied by an English language translation thereof.   |
| 16 | HIATT et al. "Drug-Eluting Stents for the Prevention of Restenosis: In Quest for the Holy Grail", <i>Catheterization and Cardiovascular Interventions</i> , vol. 55 (2002), pp. 409-417.   |
| 17 | CURFMAN "Sirolimus-Eluting Coronary Stents," <i>New England Journal of Medicine</i> , vol. 346, no. 23 (2002), pp. 1770-1771.  |
| 18 | MORICE et al. "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization," <i>New England Journal of Medicine</i> , vol. 346, no. 23 (2002), pp. 1773-1780.                                    |

DATE CONSIDERED 07/20/2010

{P29491 00092786.DOC}